Objectives: To investigate (a) the magnitude and durability of symptom score reduction and HRQL score improvement (including sexual drive); (b) adverse outcomes; and (c) progression to acute urinary retention and prostate surgery up to three years of treatment with alfuzosin.
Introduction
Benign prostatic hyperplasia can now be considered as a benign anatomical and clinical disease. 1 Medical therapy, and particularly alpha-blockade therapy, has been extensively studied in double-blind placebo-controlled studies by urologists on outpatients, and usually in hospital setting. 2 Those ef®cacy studies have consistently demonstrated the ef®cacy and safety of alpha 1 -blocker in the treatment of BPH. 3 In particular alfuzosin has been proven to have a good bene®t/risk ratio. 4, 5 Because of the increasing number of diagnoses in younger patients and the longer life expectancy in men it became necessary to conduct long-term outcomes to understand better the natural history of the disease and the factors that are likely to in¯uence its evolution. 6 Long-term open-labelled studies have been previously conducted in small populations of BPH patients initially enrolled in double-blind trials and secondarily followed-up in an open way, but they concerned a small number of carefully selected patients in urological practices and they did not address Quality of Life measurement. 7±9 Moreover, a number of authors pointed to the fact that symptom frequency and the degree of bladder obstruction are not well correlated 10 and does not necessarily re¯ect the patient's viewpoint in relation to his disease. 11 Patient's preferences have been proven to be the major in¯uence in the therapeutic choice in BPH and may be different from those of urologists. As mentioned by Rosier and coworkers, 12 the urologist's priorities were based on the degree of obstruction (peak-¯ow, residual urine measurement, pressure-¯ow studies) while patients are mostly bothered by storage symptoms and especially urgency, nocturia and daytime frequency. 13 It is stated that the degree to which urinary dif®culties bother the BPH patient and affects his daily activities varies considerably among individual patients reporting the same symptoms.
14 So the Third International WHO Conference on BPH 15 and the AHCPR guidelines 11 recommended assessing Quality of Life in BPH patients with validated tools complementary to symptom frequency (IPSS) 16 and degree of bothersomeness (BPH Impact Index) 17 measurements. In the context of medical outcomes studies it was then mandatory to perform studies able to address the issues of the contemporary management of BPH: What about the long-term effectiveness and safety of alpha-blockers? What about the incidence of surgery or complications on large cohorts of patients medically treated up to three years? What are the relationships between symptom frequency and Health Related Quality of Life at baseline and during the course of the treatment? Is the patient's perceived Quality of Life improved or worsened up to 36 months?
As recommended by the FDA 18 Quality of Life claims should be supported by ®ndings based on instruments that measure all HRQL domains and, particularly, a disease-speci®c validated HRQL tool is a priori a better instrument than a single disease-speci®c question. So we developed a self-administered disease speci®c Health Related Quality of Life (HRQL) questionnaire comprising 20 visual analogue scale items and exploring four dimensions including patient's perceived sexual life assessment (BPHQL20ÐUrolife   TM   ) . 19 Previous data have shown the ef®cacy and safety of alfuzosin in randomised double-blind placebo controlled studies 20, 21 and in open labelled studies up to 3, 12, and 24 months. 22±24 Finally it could be stated that alpha 1 -blocker clinical uroselectivity assessment should primarily evaluate bene®t/risk ratio; but safety pro®le must be completed by the construction and the study of a large patient data-base including non selected patients such as the middle-aged, the elderly and those taking multiple medications.
The aims of this three year open-labelled study were to investigate a number of aspects including: (1) the magnitude and durability of symptom score improvement; (2) the effect on patients' perceived HRQL and sexuality; (3) adverse events and treatment failure; and (4) progression to acute urinary retention and prostate surgery.
Methods
Patients enrolled in the cohort study gave informed consent, were aged less than 85 y, had clinical BPH and were willing to accept treatment for three months. Concomitant medication with another alpha-1 blocker was prohibited, but use of plant extracts were permitted if such treatment was not initiated or modi®ed during the trial. Patients were excluded if they had urological symptoms due to another urinary tract disorder, had previously undergone prostate surgery, or were scheduled for surgery within the following three months.
Initially the study protocol was designed to follow patients up to three months but the duration of the protocol was subsequently extended to three years as following: at the end of the 3, 12, and 24 month-period of treatment the centers were asked whether they wished to continue or to stop the study. Table 1 summarizes the number of centers who accepted to continue the study per period. The data concerning the follow-up of the patients from 0±3 months and 0±12 months have already been published; 22, 23 for the 0±36 month period the data are in press. 24 Alfuzosin was prescribed under usual general practice prescribing conditions, in accordance with data recommendations for use of the drug in France. The dosage regimen was alfuzosin tablets 2.5 mg tid (7.5 mg/d) for 36 months. Symptoms were measured using a standardised self-administered BPH symptom questionnaire (including the nine items of the Boyarsky score 25 and one additional item`Straining to void') completed at the General Practitioner's (GP) of®ce at baseline and at 1, 3, 6, 12, 18, 24, 30, and 36 months. Symptoms were classi®ed as storage (`irritative') (day-time frequency, nocturia, urgency) or voiding (`obstructive') (quality of urine stream, feeling of incomplete voiding, straining to urinate, intermittency) symptoms. Each question scored from 0±4 and so the global scoring questionnaire ranged from 0±40. Patients were strati®ed according to symptom severity: mild symptoms (0±13), moderate symptoms (14±26), and severe symptoms (27±40).
HRQL was measured with a validated disease speci®c HRQL questionnaire (Urolife TM BPHQL20) 19 using a selfadministered questionnaire completed at the GPs of®ce at baseline and 3, 6, 12, 18, 24, 30, and 36 months. This speci®c questionnaire consisted of 20 questions (Table 2) , which were scored on 10 cm visual analogue scales (VAS): therefore the minimum and maximum scores for each question were 0 and 10, respectively. The global HRQL scale was calculated by summation of the 20 VAS scores for the physical/functional dimension (six questions), social life dimension (six questions), mental health dimension (six questions), and overall QoL dimension (two questions). The sum of the scores for each group of questions gave three corresponding subscores (minimum: 0, maximum: 60) and an overall QoL subscore (minimum: 0, maximum: 200) was calculated by combining the three subscores and those of the two general questions. Three questions explored the patient's perceived sexual life status: two were from the physical/functional subscore (sexual desire, quality of erection) and one from the social subscore (satisfaction with sexual life). They were analysed separately by constructing a sexuality subscore (minimum: 0, maximum: 30) from the responses to the three sexuality questions.
Safety was assessed by collecting reports of adverse events (AEs) in an open mode and by sitting blood pressure and heart rate measurements at each visit.
As this was a non-randomised study, statistical analysis was primarily performed using descriptive parameters (incidence, percentage, mean, standard deviation, quantiles, and histograms of incidence). Demographic characteristics and safety were analysed in an intent-to-treat way. Analysis for possible ef®cacy-related factors was carried out by simple regression, w 2 test, or an analysis of variance (ANOVA), depending on the type of data. All analyses were two-tailed with a level of 5%. Data changes were analysed by (a) measurement of absolute variation (last value-baseline value); (b) measurement of relative variation ([last value 7 baseline value/baseline value]); and (c) measurement of magnitude of therapeutic effect: Effect Size Index (ESI) ([last value 7 baseline value]/ baseline value standard deviation) and Guyatt's responsiveness statistic (mean change among all patients divided by the standard deviation of the changes among patients rating themselves unimproved). For discrete variables, analysis was carried out using the w 2 test, 
r 0.34, P`0.0001) and with symptom severity (r 7 0.46, P 0.0001) ( Table 3) .
Effect of treatment
Symptom score (Boyarsky modi®ed) ( Table 4) . Baseline Boyarsky modi®ed symptom score (17.6 AE 0.1) was signi®-cantly reduced (P 0.0001) at 3, 6, 12, 18, 24, 30, and 36 months (Figure 1 ). The onset of maximum symptom reduction occurred at 3 months (79.87 AE 0.11; 754.05%) and was maintained up to three years (79.65 AE 0.16; 748.42%). HRQL score (Urolife TM BPH QoL 20) (Table 4) . Baseline HRQL score (90.4 AE 6) was signi®cantly (P`0.0001) improved at 3, 6, 12, 18, 24, 30, and 36 months ( Figure 1) ; The onset of maximum HRQL improvement occurred at 12 months ( 25.1 AE 0.77; 45.4%) and was maintained up to three years ( 21.4 AE 0.9; 43.4%). Physical/functional dimension was more improved (ESI 0.88) than social dimension (ESI 0.62), mental dimension (ESI 0.45), and patient's perceived sexual dimension (ESI 0.37). HRQL improvement was more correlated with baseline symptom severity than with age (Table 6 ); in each age class signi®cative differences were noted by initial symptom severity classes: the patients reporting the most severe symptoms at baseline were more improved than the other patients; no differences due to age were noted in the mild to moderate patient groups for HRQL improvement but in patients reporting the most severe symptoms the younger reported a greater HRQL improvement than the older (P 0.0004). Patient's perceived sexual life subscore improvement was strongly inversely correlated with age and with initial symptom severity; according to ESI b 0.50 and age it was signi®cantly improved in patients reporting severe symptoms at baseline whatever their age: 1.04, 1.06, and 0.67 in younger, middle-aged and older patients, respectively.
The magnitude of effect (ESI) for Symptom and HRQL was more correlated with initial symptoms score than with age. Out of the 1688 patients who completed both symptom and HRQL scores at baseline at three years 1340, 300, and 48 reported symptom improvement (ESI b 0.5), symptom stability (0.5: 70.5), and symptom worsening (`70.5), respectively. Table 7 shows the correlation existing between symptom and HRQL changes in the different groups of patients: in the group of patients reporting symptom improvement 11.5% reported worsening of their Quality of Life; in the group Figure 1 Changes in symptom and HRQL scores up to three years. 
Patients who underwent surgery
One hundred and twenty out of 3228 patients (3.7%) underwent surgery during the course of the treatment. For the whole study the percentage of patients operated on was highest during the 3±12 month period (0.37%) and did not increase with time. The patients operated on experienced lesser improvement (ESI) of symptoms than other patients (0.25 vs 1.29, respectively, P`0.0001).
Acute urinary retention
The number of episodes of acute urinary retention (AUR) was extremely low (n 9; 0.3%): in the 24±36 months of treatment the rate was 0.09% per month.
Discussion
The contemporary management of BPH is in transition. 26 The common and chronic condition of BPH results in a varied population of non-selected BPH-patients, such as middle-aged, sexually active, and the elderly with a high rate of comorbidity, are likely to be treated. This three year outcome study is an opportunity to learn more about the natural history of BPH in a population of unselected men seeking and receiving alpha1-blockade therapy in general practice: long-term effectiveness studies are actually relevant in the perspective of individual treatment decision making and can provide information on how to manage such a chronic disease and how to inform patients about their condition. 6 It is no longer possible to argue that classical measurements such as symptom frequency, uro¯owmetry, and residual urine, are the unique criteria for assessing the satisfaction of the patients:
11 they expect more. 27 Paradoxically, at the moment where it has been proven that surgery is effective and safe, 1 pharmacological and invasive alternatives to prostatectomy are likely to replace surgery 28 with probably a diminished ef®cacy. 29 It is likely that many patients will opt for a treatment that may be less effective in improving symptoms and¯ow rates but carries a lower risk of complications. 27 This study can be construed as an effectiveness study addressing the long-term view-point of the patient by assessing how the disease-speci®c health status of BPH-patients was affected by the treatment in the pragmatic situation of general practice.
An open-labelled study was conducted without a control group because, in France, it was not possible to enrol BPH patients who agreed to watchful waiting during a period of 36 months. In such a community practice setting it was not possible to measure bladder outlet obstruction and subsequent studies have proven that surgery 30 or alpha1-blocker therapy 31 lead to the same symptom reduction whatever the initial degree of bladder outlet obstruction. The American Urological Association (AUA) 32 and International Prostate Symptom Score (I-PSS) 33 index scores were not used here because they did not exist when this trial was initiated; subsequently, the Boyarsky score has been shown to correlate well with the AUA symptom score. 34 BPH patients enrolled in this study were representative of a population of treated patients in general practice and were similar to that of other out-patient populations studied as much for age as for prostate volume or PVR.
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The overall results of the study could primarily indicate that the strong inverse correlation existing between symptom score reduction (748.4%) and HRQL improvement ( 43.4%) after a three year alfuzosin treatment could avoid the necessity to measure the latter ( Figure  1 ) but a number of facts highlight the need to assess HRQL complementary to symptom measurement at baseline and during the course of the treatment. At baseline the correlations of symptom score with HRQL score were weak (r 7 0.46; P 0.0001) compared with the correlation found in a general French population between total symptom score and bothersome score (r 0.85): it is likely Clinical BPH patients treated with alfuzosin B Lukacs et al that HRQL measurement addresses a different domain to the bothersome measurement. It was also con®rmed that HRQL and patient's perceived sexual subscore were more correlated with initial symptom severity than with age: r 7 0.26, P`0.0001 and r 7 0.46, P`0.0001, respectively, for the former score and r 7 0.34, P`0.0001 and r 7 0.46, P 0.0001, respectively, for the latter score. During the course of the treatment: the discrepancy between the early onset of maximum symptom score reduction at three months (754%) and the delayed onset of maximum HRQL improvement at twelve months ( 45%) emphasizes the need to measure longterm outcomes according to the patient's perspectives. In the same way, symptom reduction and HRQL improvement were sustained up to 36 months (748% and 43%, respectively); interestingly the storage score was signi®-cantly more reduced than voiding score, and it had been shown that the former was perceived by the patients as the most bothersome 12 and correlated more with HRQL changes. 38 Physical/functional dimension improved more than social life status and mental dimensions, which contrasts with ®ndings of Fowler and coworkers 39 and of Doll and colleagues 40 in patients who underwent surgery (prostatectomy and transurethral resection of prostate, respectively). These data con®rm the importance of disease-speci®c HRQL measurements, which are better able than generic instruments to detect changes due to treatment. In particular, signi®cant changes in patient's perceived sexual life subscore were detected; the magnitude of this global improvement (ESI 0.37) was weak, but Table 5 underlines the fact that it is more strongly correlated with symptom severity than with age. Patient's perceived sexual life subscore was signi®cantly more improved in the patients reporting the most severe symptoms at baseline whatever their age. These data were in contradiction to those observed in a long-term ®nasteride study with regard to stimulation sexual function. 41 It is important to distinguish clinical sexual score assessment 42 from the patient's perception of his sexual life. In BPH a majority of patients do not complain about sexual function, but are still interested in treatments that are supposed to interfere least with their sexual life status.
Alfuzosin was well tolerated: the quantitative and qualitative distribution of adverse events was similar to that previously observed in placebo-controlled studies. 20, 21 Two hundred and forty-®ve patients (7.6%) died during this three year study, which is consistent with the chance of dying (0.8% per 90 d) in a similar population of men. 11 The percentage of AEs leading to the discontinuation from the study is low (4.2%) as compared to that of a 42-month open trial conducted with terazosin in BPH patients (19%) 8 or a 48-month open trial conducted with doxazosin in normotensive and hypertensive BPH patients (15.1% and 19.1%, respectively.) 9 The percentages of patients (3.7%) operated on and experiencing acute urinary retention (0.3%) during this General Practice three-year follow-up were dramatically lower than in a watchful waiting study including symptomatic BPH patients reporting moderate symptoms followed-up in urological setting: 24% and 2.9%, respectively. 43 The present data highlight the necessity to conduct effectiveness studies, (that is, how effective the drug is in a selected patient population), complementary to ef®cacy studies, that is, how the drug works in the community setting and how the patient perceives his treatment. HRQL assessment in BPH patients is necessary to capture the impact of symptoms on patient's health status: it explores different dimensions to symptom score assessment and must include sexual function. It seems now mandatory to assess any therapeutic intervention with validated tools measuring symptoms, safety pro®le and HRQL.
